Maximum Tolerated Dose (MTD) Evaluation of PIP4Kga
Closed Solicitation Posted
- Solicitation number
- 75N98026Q00989
- Agency
-
Office of Logisitics and Acquisition Operations
National Institutes of Health, Department of Health and Human Services
- Responses due
- Set-aside
- No set-aside
Opportunity facts
- NAICS code
- 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
- PSC
- Q301 Reference Laboratory Testing
- Points of contact
Notice details come from SAM.gov. Updated .
About this opportunity
The National Institutes of Health, Office of the Director, seeks a firm-fixed-price contract for a non-GLP maximum tolerated dose evaluation study of PIP4Kgamma lead compound NCGC00592266 in mice, with proposals due August 24, 2026 at 8:00 AM EST. The acquisition is unrestricted, fully open competition under FAR 12.603 for commercial services.
Place of performance and delivery requirements are not specified in the source. The period of performance runs from September 4, 2026 to October 30, 2026, with documentation and findings presented to NCATS via email and conference calls approximately one month following study initiation.
The scope requires a non-GLP MTD study using CD-1 SPF mice with five dose groups (three male and three female mice per group, 30 total animals). The compound will be administered via intraperitoneal injection, with dose levels determined in consultation with NCATS prior to study initiation. Contractor responsibilities include animal acclimation and veterinary supervision, dose formulation preparation, clinical observations, post-dose monitoring, body weight monitoring, necropsy and tissue preservation, and preparation of a standard non-GLP study report. The estimated level of effort requires one PhD-level Study Director, one Scientist, and technical/animal care staff for approximately three weeks in-life phase plus reporting. NCATS provides the required compound, handling and formulation information, and technical consultation.
Deliverables include the MTD study report, clinical observation summaries, body weight data, mortality and toxicity observations, and necropsy findings, delivered electronically to Tej Poudel and Juan Marugan. The NAICS code is 541715 with a small business size standard of 1,000 employees. Evaluation factors are price, technical capability, past performance, and delivery schedule. All offerors must be actively registered in SAM. Award value or budget ceiling is not stated in the source.
Notice text
(i) This is a combined synopsis/solicitation for commercial items prepared in accordance with FAR Subpart 12.6, as supplemented with additional information included in this notice. This announcement constitutes only solicitation; proposals are being requested, and a separate written solicitation will not be issued.
(ii) The solicitation number is 75N98026Q00989. This solicitation is issued as a competitive combined synopsis/solicitation for commercial products or commercial services. The Government intends to award a contract or purchase order resulting from this solicitation using full and open competition.
This acquisition is conducted under the authority of FAR 12.603, Streamlined Solicitation for Commercial Products or Commercial Services, and is not expected to exceed the simplified acquisition threshold (if applicable).
The National Institutes of Health (NIH), Office of the Director, Office of Acquisitions, seeks to award a (Firm-Fixed-Price) to the offeror responsible whose proposal represents the best value to the Government.
(iii) The solicitation document and incorporated provisions and clauses are those in effect through Federal Acquisition Circular effective August 7, 2026
(iv) The associated NAICS code is 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology) and the small business size standard is 1000 employees.
This requirement is unrestricted.
Files
| File | Type | Posted |
|---|---|---|
| Sol_75N98026Q00989.pdf |
Similar open opportunities
| Opportunity | Agency | Set-aside | Responses due |
|---|---|---|---|
| Stability Testing for ManNAc Drug Product produced in Campaigns 5 and 6. Stability testing will occur under regulatory compliance | Office of Logisitics and Acquisition Operations | No set-aside |
On GovTribe
Work this opportunity
- Track it in your pipeline
- Find teaming partners
- Similar opportunities
- Ask GovTribe AI about this opportunity